Cas no 75607-67-9 (Fludarabine phosphate)

Fludarabine phosphate is a purine analog and antimetabolite chemotherapeutic agent, primarily used in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. Its active metabolite, 2-fluoro-ara-ATP, inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to apoptosis in rapidly dividing cells. The phosphate formulation enhances solubility, allowing for intravenous or oral administration. Fludarabine phosphate is valued for its targeted mechanism of action, efficacy in refractory cases, and compatibility with combination therapies. It requires careful hematologic monitoring due to potential myelosuppression. The compound is widely utilized in clinical oncology for its established therapeutic profile.
Fludarabine phosphate structure
Fludarabine phosphate structure
Product Name:Fludarabine phosphate
CAS No:75607-67-9
MF:C10H13FN5O7P
MW:365.21168589592
MDL:MFCD00866418
CID:59705
PubChem ID:30751
Update Time:2025-11-27

Fludarabine phosphate Chemical and Physical Properties

Names and Identifiers

    • Fludarabine Phosphate
    • 9-beta-d-arabinofuranosyl-2-fluoroadenine5’-monophosphate
    • fludarabinemonophosphate
    • 9-bata-d-arabinofuranosyl-2-fluoroadenine phosphate
    • 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE-5'-DIHYDROGEN PHOSPHATE
    • FLUDARUBINE PHOSPHATE
    • FludarabinePhosphateFdaInspected
    • FludarabinePhosphateUsp28
    • FLUDARABIN PHOSPHATE,USP30
    • Fludarabine (phosphate)
    • Fludarabine 5'-Phosphate
    • 2-Fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amine
    • 2-fluoro-araamp
    • 2-fluoro-ara-C-5'-O-phosphate
    • FAMP
    • F-ara-AMP
    • Fludarabin Phosphate
    • fludarabine
    • fludarabine hcl
    • Fludarabine Phosphate (Fludara)
    • Fludura
    • 9-(β-D-Arabinofuranosyl)-2-fluoroadenine 5'-Monophosphate
    • 2-F-ara-AMP
    • 2-Fluoroadenine 9-β-D-Arabinofuranoside 5'-Monophosphate
    • fludara
    • Fludarabine 5'-monophosphate
    • Oforta
    • 2-Fluoro-ARA AMP
    • Fludarabine monophosphate
    • C10H13FN5O7P
    • 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine
    • 2-Fluoroadenine arabinoside 5'-monophosphate
    • 1X9VK9O1SC
    • 9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
    • 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
    • CHE
    • NSC 118218 phosphate
    • Z2235802254
    • FLUDARABINE PHOSPHATE [MART.]
    • F-ara-A (NSC 312887) Phosphate
    • FaraAMP
    • 9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate
    • SHT-586
    • NSC 328002
    • 2-Fluoro-ara-AMP
    • SMR002544683
    • HMS2094O11
    • s1229
    • FLUDARABINE PHOSPHATE [USP MONOGRAPH]
    • [rac-(2R,3S,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate
    • FLUDARABINE 5'-MONOPHOSPHATE [MI]
    • MLS003915617
    • MLS004774150
    • Q185916
    • FLUDARABINE PHOSPHATE (MART.)
    • AS-14202
    • Fludarabine phosphate (JAN/USP)
    • Beneflur
    • SBI-0206893.P001
    • [(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
    • NSC312887
    • NSC-312887
    • 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-
    • 9-.beta.-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
    • 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-b-D-arabinofuranosyl)-
    • A838460
    • Fludarabine phosphate; 2-Fluoro-9-(5-O-phosphono-?-D-arabinofuranosyl)-9H-purin-6-amine
    • fludara Phosphate
    • NSC 312887 Phosphate
    • BCP0726000268
    • NSC759194
    • 75607-67-9 (phosphate)
    • 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
    • NSC-759194
    • FLUDARABINE PHOSPHATE [JAN]
    • 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-
    • SCHEMBL3511
    • FLUDARABINE PHOSPHATE [USP-RS]
    • CHEMBL1096882
    • DTXCID103060
    • SR-05000001945-1
    • DTXSID2023060
    • ((2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate
    • Pharmakon1600-01505705
    • Fludarabine phosphate (USAN:USP:BAN)
    • MFCD00866418
    • Fludarabine for system suitability
    • fludarabine-phosphate
    • fluoro-ara-AMP
    • HY-B0028
    • D01907
    • FLUDARABINE PHOSPHATE [ORANGE BOOK]
    • Fludarabine phosphate;
    • FLUDARABINE PHOSPHATE [VANDF]
    • SR-05000001945
    • FLUDARABINE PHOSPHATE (USP MONOGRAPH)
    • Fludarabine Phosphate(Fludara)
    • SRI-5907-04
    • CHEBI:63599
    • NSC-328002
    • SW218146-2
    • AKOS024464516
    • 75607-67-9
    • SRI-5907_07
    • {[(2R,3S,4S,5R)-5-(6-AMINO-2-FLUORO-9H-PURIN-9-YL)-3,4-DIHYDROXYOXOLAN-2-YL]METHOXY}PHOSPHONIC ACID
    • BDBM50248004
    • HG1010
    • FLUDARABINE PHOSPHATE (USP-RS)
    • Fludarabine phosphate [USAN:USP:BAN]
    • SR-05000001945-4
    • UNII-1X9VK9O1SC
    • FLUDARABINE PHOSPHATE [EP MONOGRAPH]
    • 2F-ara-AMP
    • FLUDARABINE PHOSPHATE (EP MONOGRAPH)
    • CCG-213521
    • EN300-269343
    • BCP9000694
    • GIUYCYHIANZCFB-FJFJXFQQSA-N
    • CS-0861
    • FLUDARABINE PHOSPHATE [USAN]
    • SRI-5907_05
    • FLUDARABINE PHOSPHATE [WHO-DD]
    • EX-A2028
    • NSC 312887
    • Fludara (TN)
    • 9-beta-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate
    • NCGC00182047-14
    • Fludarabine phosphate; 2-Fluoro-9-(5-O-phosphono-ss-D-arabinofuranosyl)-9H-purin-6-amine
    • GLXC-03004
    • BRD-K71106091-001-06-1
    • Fludarabinephosphate
    • Fludarabine phosphate?
    • BRD-K71106091-001-05-3
    • BRD-K71106091-001-09-5
    • Fludarabine phosphate
    • MDL： MFCD00866418
    • Inchi： 1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1
    • InChI Key： GIUYCYHIANZCFB-FJFJXFQQSA-N
    • SMILES： P(=O)(O)(O)OC[C@@H]1[C@H]([C@@H]([C@H](N2C=NC3C(N)=NC(=NC2=3)F)O1)O)O

Computed Properties

  • Exact Mass: 365.05400
  • Monoisotopic Mass: 365.054
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 5
  • Hydrogen Bond Acceptor Count: 12
  • Heavy Atom Count: 24
  • Rotatable Bond Count: 4
  • Complexity: 514
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 3
  • XLogP3: -3.1
  • Topological Polar Surface Area: 186

Experimental Properties

  • Color/Form: White to Yellow Solid
  • Density: 2.39±0.1 g/cm3(Predicted)
  • Melting Point: 203°C(dec.)(lit.)
  • Boiling Point: 864.2±75.0 °C at 760 mmHg
  • Flash Point: 476.4±37.1 °C
  • Refractive Index: 1.878
  • Solubility: DMSO: soluble1mg/mL
  • Water Partition Coefficient: Soluble in DMSO or water at 5mg/ml
  • PSA: 195.88000
  • LogP: -1.14270
  • Merck: 4126
  • Specific Rotation: +13° (c=5, H2O)
  • Sensitiveness: Easily absorb moisture
  • Solubility: Slightly soluble in water and organic solvents. Monophosphate is soluble in water.
  • Vapor Pressure: 0.0 ± 0.3 mmHg at 25 ° C

Fludarabine phosphate Security Information

  • Symbol: GHS07
  • Prompt：warning
  • Signal Word：Warning
  • Hazard Statement： H315,H319,H335
  • Warning Statement： P261,P305
    P351
    P338,P302
    P352,P321,P405,P501A
  • Hazardous Material transportation number：UN 2811 6.1/PG 3
  • WGK Germany：3
  • Safety Instruction： S45
  • RTECS：UO7440900
  • Hazardous Material Identification： Xi
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
  • Risk Phrases：R25

Fludarabine phosphate Customs Data

  • HS CODE：2934999090
  • Customs Data：

    China Customs Code:

    2934999090

    Overview:

    2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Fludarabine phosphate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
F0913-100MG
Fludarabine Monophosphate
 75607-67-9 >98.0%(T)(HPLC)
100mg
 ￥290.00 2024-04-15
S e l l e c k ZHONG GUO
S1229-10mg
Fludarabine Phosphate
 75607-67-9 99.94%
10mg
 ￥814.19 2023-09-16
S e l l e c k ZHONG GUO
S1229-50mg
Fludarabine Phosphate
 75607-67-9 99.94%
50mg
 ￥2433.27 2023-09-16
S e l l e c k ZHONG GUO
S1229-100mg
Fludarabine Phosphate
 75607-67-9 99.94%
100mg
 ￥4070.43 2023-09-16
S e l l e c k ZHONG GUO
S1229-200mg
Fludarabine Phosphate
 75607-67-9 99.94%
200mg
 ￥4886.93 2023-09-16
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R016811-1g
Fludarabine phosphate
 75607-67-9 99%
1g
 ￥1076 2023-09-07
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R016811-250mg
Fludarabine phosphate
 75607-67-9 99%
250mg
 ￥318 2023-09-07
ChemScence
CS-0861-10mg
Fludarabine phosphate
 75607-67-9 ≥98.0%
10mg
 $66.0 2022-04-26
ChemScence
CS-0861-50mg
Fludarabine phosphate
 75607-67-9 ≥98.0%
50mg
 $145.0 2022-04-26
ChemScence
CS-0861-100mg
Fludarabine phosphate
 75607-67-9 ≥98.0%
100mg
 $185.0 2022-04-26

Fludarabine phosphate Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:75607-67-9)Fludarabine phosphate
Order Number:A838460
Stock Status:in Stock
Quantity:5g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 06:43
Price ($):375.0
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:75607-67-9)Fludarabine Phosphate
Order Number:LY0051
Stock Status:in Stock
Quantity:1KG
Purity:98%standard
Pricing Information Last Updated:Wednesday, 30 July 2025 14:20
Price ($):Inquiry
Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:75607-67-9)Fludarabine phosphate
Order Number:sfd16655
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:37
Price ($):discuss personally
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:75607-67-9)Fludarabine(phosphate)
Order Number:LE18077;LE6073558
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:17
Price ($):discuss personally

Fludarabine phosphate Spectrogram

1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Fludarabine phosphate Related Literature

Related Categories

Additional information on Fludarabine phosphate

Recent Advances in Fludarabine Phosphate (75607-67-9) Research: A Comprehensive Review

Fludarabine phosphate (CAS: 75607-67-9), a purine nucleoside analog, has long been a cornerstone in the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphomas. Recent studies have expanded our understanding of its mechanisms of action, resistance patterns, and potential applications in novel therapeutic combinations. This research brief synthesizes the latest findings from peer-reviewed literature and clinical trial data to provide a current perspective on fludarabine phosphate's role in modern oncology and emerging biopharmaceutical applications.

A 2023 study published in Blood Advances revealed new insights into fludarabine phosphate's immunomodulatory effects when combined with CD19-targeted CAR-T cell therapy. Researchers demonstrated that pretreatment with fludarabine phosphate enhances CAR-T cell expansion and persistence by creating an immunologically favorable microenvironment through selective lymphocyte depletion. The study (NCT04082429) showed a 38% improvement in complete response rates compared to non-chemotherapy conditioning regimens, suggesting potential optimization of lymphodepletion protocols.

Pharmacogenomic research has identified novel biomarkers predictive of fludarabine phosphate sensitivity. A multi-center genome-wide association study (Nature Cancer, 2024) correlated specific single nucleotide polymorphisms (SNPs) in the DCK (deoxycytidine kinase) and NT5C2 (5'-nucleotidase) genes with treatment response variability. These findings may enable personalized dosing strategies to maximize efficacy while minimizing hematologic toxicity, particularly in elderly patients with compromised bone marrow reserve.

Innovative drug delivery systems for fludarabine phosphate are under active investigation. A recent breakthrough in the Journal of Controlled Release (2024) described a tumor-targeted nanoparticle formulation that demonstrated 5.7-fold increased accumulation in lymphoid tissues compared to conventional administration. This nanotechnology approach reduced systemic exposure while maintaining therapeutic concentrations in malignant cells, potentially addressing the drug's dose-limiting myelosuppressive effects.

The drug's chemical stability and formulation challenges remain areas of active research. Analytical chemistry studies (Journal of Pharmaceutical Sciences, 2023) have developed improved HPLC-MS methods for detecting fludarabine phosphate degradation products, particularly the inactive 2-fluoro-ara-A metabolite. These advancements support quality control in both pharmaceutical manufacturing and clinical laboratory monitoring.

Emerging evidence suggests potential applications beyond oncology. Preclinical studies in Science Translational Medicine (2023) reported fludarabine phosphate's efficacy in modulating allogeneic immune responses in stem cell transplantation, with particular promise for graft-versus-host disease (GVHD) prophylaxis. The drug's ability to selectively deplete certain lymphocyte subsets while preserving regulatory T cells may open new therapeutic avenues in autoimmune disorders and transplant medicine.

Ongoing clinical trials continue to refine fludarabine phosphate's therapeutic index. The phase III REFINE study (NCT05223101) is currently evaluating reduced-intensity conditioning regimens combining fludarabine phosphate with newer agents like venetoclax in older CLL patients. Preliminary data presented at ASH 2023 showed comparable efficacy with significantly reduced hematologic toxicity compared to traditional FCR (fludarabine, cyclophosphamide, rituximab) regimens.

In conclusion, fludarabine phosphate remains a molecule of significant research interest nearly four decades after its initial approval. Contemporary studies are elucidating its complex immunopharmacology, optimizing its clinical use through precision medicine approaches, and exploring innovative formulations to overcome historical limitations. These advancements promise to extend the drug's clinical utility while improving patient outcomes across multiple therapeutic areas.

75607-67-9 (Fludarabine phosphate) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:75607-67-9)Fludarabine phosphate
A838460
Purity:99%
Quantity:5g
Price ($):375.0
Email
Hebei Liye chemical Co.,Ltd
(CAS:75607-67-9)Fludarabine Phosphate
LY0051
Purity:98%standard
Quantity:1KG
Price ($):Inquiry
Email